Vyant Bio Commences a Cash Preservation Plan Including a Reduction in Force
February 03, 2023 06:00 ET
|
Vyant Bio, Inc.
Continuing to Explore Strategic Alternatives CHERRY HILL, N.J., Feb. 03, 2023 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio” or “Company”) (Nasdaq: VYNT) is an innovative biotechnology company...
Cancer Genetics Reports Third Quarter 2020 Financial Results
November 12, 2020 16:25 ET
|
Cancer Genetics, Inc.
RUTHERFORD, N.J., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (the “Company”) (Nasdaq: CGIX), a leader in drug discovery and preclinical oncology and immuno-oncology services, announced...
Cancer Genetics Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Strategic Business Updates
June 01, 2020 08:00 ET
|
Cancer Genetics, Inc.
RUTHERFORD, N.J., June 01, 2020 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq: CGIX), a leader in drug discovery and preclinical oncology and immuno-oncology services, today announced financial...